ArticleNPJ precision oncology2025
Single-cell integration analysis reveals molecular signatures of the tumor microenvironment in early-onset colorectal cancer.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Early-onset colorectal cancer: a comprehensive review reframing hypotheses and defining research priorities.International journal of colorectal disease · 2026Review
- The Molecular Signature of Early-Onset Colorectal Cancer Liver Metastases: Distinct Biology and Clinical Challenges.International journal of molecular sciences · 2026Review
- A mitoxyperilysis-related signature stratifies prognosis and identifies an aggressive colorectal cancer ecosystem with immune remodeling.Frontiers in cell and developmental biology · 2026Article
- Cytotoxic T-cell exhaustion analyses by in situ single-cell immunofluorescence in relation to colorectal cancer patient age, tissue bacteria and mortality.BMJ oncology · 2026Article
- Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy.Frontiers in immunology · 2026Article
- Integrated multi-omics characterization of SPTBN2 overexpression reveals its pro-tumorigenic role and immune microenvironment remodeling in colorectal cancer.Frontiers in cell and developmental biology · 2026Article
- Diagnostic Pathways and Molecular Biomarkers in Colorectal Cancer: Current Evidence and Perspectives in Poland.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The incidence of early-onset colorectal cancer (CRC), defined as cases diagnosed in individuals under 50, is rising globally. However, its molecular and immune characteristics remain poorly understood. In this study, we analyze single-cell RNA sequencing data from 168 CRC patients, aged 22 to 91, to investigate differences between early-onset and standard-onset CRC. We find a reduced proportion of tumor-infiltrating myeloid cells, a higher burden of copy number variations, and decreased tumor-immune interactions in early-onset CRC. Additionally, immune signatures unique to early-onset CRC are associated with differential responses to immunotherapy, underscoring the need for tailored therapeutic strategies for this group of patients. These findings provide valuable insights into the molecular and immune landscape of early-onset CRC, emphasizing the importance of developing targeted prevention and treatment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.